Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianpi Yiqi oral liquid is a Traditional Chinese Medicine (TCM) Class 1.1 new drug developed by the First Affiliated Hospital of Guangxi University of Chinese Medicine. It is formulated from eight herbal ingredients: Codonopsis pilosula (Dangshen), Citri Reticulatae Pericarpium (Chenpi), Astragali Radix (Huangqi), Atractylodis Macrocephalae Rhizoma (Baizhu), Polygoni Multiflori Radix Praeparata (Zhiheshouwu), Ophiopogonis Radix (Maidong), Tritici Fructus Levis (Fuxiaomai), and Gigeriae Galli Endothelium Corneum (Jineijin). The formulation is designed to strengthen the spleen and replenish qi, and is primarily developed for the treatment of pediatric functional dyspepsia. In China, the clinical trial application for Jianpi Yiqi oral liquid has received implied permission from the National Medical Products Administration (NMPA).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jianpi yiqi oral liquid.